APPENDIX A

1.   (amended) A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an immune response with an immunologically effective amount of a composition comprising a [phosphatidylserine/ polypeptide] lipid or lipid/polypeptide conjugate.

2.   The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.

3.   The method of claim 1, wherein said cancer cell is comprised within an animal.

4.   The method of claim 3, wherein said animal is a human.

5.   The method of claim 1, wherein said composition further comprises a pharmaceutical excipient.

6.   The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.

7.   (amended) The method of claim 1, wherein said [polypeptide is] immune response is elicited with lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.

8.   The method of claim 7, wherein said polypeptide is β_2-glycoprotein I.

11.   (amended) The method of claim [8] 7, wherein said lipid is phosphatidylcholine or phosphatidylserine.

12.   A method of generating an immune response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.

28. The method of claim 1, wherein said lipid or lipid/polypeptide conjugate is phosphatidylserine or a phosphatidylserine/polypeptide conjugate.

29. The method of claim 3, wherein said animal has cancer.

30. The method of claim 29, wherein said animal has a tumor.

31. The method of claim 4, wherein said human has cancer.

32. The method of claim 31, wherein said human has a tumor.

33. The method of claim 12, wherein said animal comprises a cancer cell.

34. The method of claim 33, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.

35. The method of claim 12, wherein said animal has cancer.

36. The method of claim 12, wherein said animal has a tumor.

37. The method of claim 12, wherein said animal is a human.

38. The method of claim 37, wherein said human has cancer.

39. The method of claim 40, wherein said human has a tumor.

40. The method of claim 12, wherein said animal is a mouse.

41. The method of claim 12, wherein said animal is a rat, a hamster, a guinea pig or a goat.

42. The method of claim 12, wherein said composition is administered to said animal topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.

43. The method of claim 12, wherein said immune response is elicited with a lipid or lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β2-glycoprotein I.

44. The method of claim 44, wherein said polypeptide is β2-glycoprotein I.